Press release
SYK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the SYK Inhibitor Treatment Landscape @ SYK Inhibitor Pipeline Outlook [https://www.delveinsight.com/sample-request/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the SYK Inhibitor Pipeline Report
* DelveInsight's SYK Inhibitor pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for SYK Inhibitor treatment.
* The leading SYK Inhibitor Companies such as Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
* Promising SYK Inhibitor Pipeline Therapies such as SKI-O-703, Entospletinib and others.
Stay informed about the cutting-edge advancements in SYK Inhibitor treatments. Download for updates and be a part of the revolution @ SYK Inhibitor Clinical Trials Assessment [https://www.delveinsight.com/sample-request/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
SYK Inhibitor Emerging Drugs Profile
* Cevidoplenib dimesylate: Genosco
The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.
* HMPL-523: Hutchison MediPharma
An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.
The SYK Inhibitor Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of SYK Inhibitor with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for SYK Inhibitor Treatment.
* SYK Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* SYK Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the SYK Inhibitor market.
Learn more about SYK Inhibitor Drugs opportunities in our groundbreaking SYK Inhibitor research and development projects @ SYK Inhibitor Unmet Needs [https://www.delveinsight.com/sample-request/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
SYK Inhibitor Companies
Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Molecule Type
SYK Inhibitor Products have been categorized under various Molecule types such as
* Monoclonal antibodies
* Small molecules
* Product Type
Stay informed about how we're transforming the future of SYK landscape @ SYK Inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the SYK Inhibitor Pipeline Report
* Coverage- Global
* SYK Inhibitor Companies- Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
* SYK Inhibitor Pipeline Therapies- SKI-O-703, Entospletinib and others.
* SYK Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* SYK Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of SYK Inhibitor Pipeline on our website @ SYK Inhibitor Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Spleen Tyrosine Kinase (SYK) Inhibitors - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
* Late Stage Products (Phase II/III)
* TOP 1630: TopiVert
* Mid Stage Products (Phase II)
* Cevidoplenib: Genosco
* PRT 2761: Portola Pharmaceuticals
* Early Stage Products (Phase I/II)
* Gusacitinib: Asana BioSciences
* Early Stage Products (Phase I)
* Mivavotinib: Takeda Oncology
* Pre-clinical and Discovery Stage Products
* Research programme: small molecule therapeutics: Genosco
* Inactive Products
* Comparative Analysis
* Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=syk-inhibitor-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SYK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4155044 • Views: …
More Releases from ABNewswire
Metastatic Non-small Cell Lung Cancer Clinical Trials, Companies, Therapeutic As …
DelveInsight's, "PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight reports that the Metastatic Non-Small Cell Lung Cancer pipeline…
Mild Cognitive Impairment Market: Epidemiology, Therapies, Companies Working, De …
The Mild Cognitive Impairment market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Mild Cognitive Impairment market size from 2020 to 2034.
Emerging therapies for Mild Cognitive Impairment, including LEQEMBI (lecanemab), KISUNLA (donanemab), and others, are anticipated to drive growth in the Mild Cognitive Impairment market in the coming years.
DelveInsight has launched a new report on "Mild Cognitive Impairment - Market…
Spasticity Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approva …
DelveInsight's, "Spasticity Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape. It covers the Spasticity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spasticity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in…
Experia Moving Expands Premium Moving Services to Greenwich, CT With Elite Team …
Experia Moving, known for elite relocation services in NYC, is now serving Greenwich, CT. With professionally trained crews, premium packing materials, and live truck tracking, Experia brings a VIP moving experience to families and businesses in Fairfield County.
Greenwich, CT - Aug 21, 2025 - Experia Moving, a trusted name in luxury relocation services in New York City, is proud to announce the expansion of its elite moving solutions to Greenwich,…
More Releases for SYK
Tyrosine Protein Kinase SYK Market Size Opportunities and Challenges for the Fut …
The global Tyrosine Protein Kinase SYK market was valued at approximately USD 1.18 billion in 2023 and is anticipated to reach around USD 3.42 billion by 2033, growing at a compound annual growth rate (CAGR) of approximately 11.3% from 2024 to 2033.
Tyrosine Protein Kinase SYK Market Overview
The Tyrosine Protein Kinase SYK market is witnessing significant momentum, driven by the increasing prevalence of autoimmune disorders, cancers, and inflammatory conditions. SYK inhibitors…
Spleen Tyrosine Kinase (SYK) Inhibitor Therapeutics Market Analysis
The global spleen tyrosine kinase (SYK) inhibitor therapeutics market was valued at approximately USD 2.1 billion in 2023 and is projected to reach USD 5.8 billion by 2033, growing at a CAGR of around 10.7% during 2024-2033.
The Spleen Tyrosine Kinase (SYK) inhibitor therapeutics market represents a rapidly evolving segment within the broader oncology and immunology pharmaceutical landscape. SYK, a non-receptor tyrosine kinase, plays a crucial role in immune cell signaling…
Unveiling Growth Trajectories: Global Tyrosine Protein Kinase SYK Market Analysi …
𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:
In the realm of molecular biology and pharmaceuticals, the Tyrosine Protein Kinase SYK (spleen tyrosine kinase) has emerged as a focal point of research and development. This intricate enzyme plays a pivotal role in signal transduction pathways within immune cells, making it a prime target for therapeutic interventions. As the global healthcare landscape navigates through the challenges posed by the COVID-19 pandemic, understanding the dynamics of the Tyrosine Protein Kinase…
Investigation announced for Long-Term Investors in shares of Stryker Corporation …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Stryker Corporation.
Investors who purchased shares of Stryker Corporation (NYSE: SYK) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Stryker officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On April 6,…
Investigation announced for Investors in shares of Stryker Corporation (NYSE: SY …
An investigation was announced concerning potential securities laws violations by Stryker Corporation in connection with certain financial statements.
Investors who purchased shares of Stryker Corporation (NYSE: SYK), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Stryker Corporation regarding its business, its prospects and its operations were materially false and…
Tyrosine Protein Kinase SYK Market Trends, Size, Competitive Analysis and Foreca …
The global tyrosine protein kinase SYK market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Tyrosine protein kinase SYK is also known as spleen tyrosine kinase (SYK). It is a non-receptor cytoplasmic enzyme and is primarily expressed in cells of hematopoietic lineage. It contains two adjacent SH2 domains that bind to immunoreceptor tyrosine-based activation motifs (ITAMs) to activate the enzyme. The major factor driving the…
